Results 1 to 10 of about 756 (179)
Eldecalcitol prevents muscle loss and osteoporosis in disuse muscle atrophy via NF-κB signaling in mice [PDF]
Skeletal Muscle, 2023 We investigated the effect of eldecalcitol on disuse muscle atrophy. C57BL/6J male mice aged 6 weeks were randomly assigned to control, tail suspension (TS), and TS-eldecalcitol–treated groups and were injected intraperitoneally twice a week with either ...
Haichao Zhang +7 more
doaj +3 more sources
Osteoporosis and Sarcopenia, 2021 Objectives: To compare the effect of eldecalcitol and alfacalcidol on skeletal microstructure by high-resolution peripheral QCT (HR-pQCT). Methods: This was a substudy of a randomized, double-blind, active comparator trial.
Mei Li, Weibo Xia, Ou Wang
exaly +4 more sources
Frontiers in Endocrinology, 2022 ObjectEldecalcitol (ED-71) is a vitamin D analog for the treatment of osteoporosis. However, inconsistent results have been reported in this regard. Hence, this meta-analysis of randomized controlled trials (RCTs) aimed to assess the efficacy and safety ...
Gu Weijun, Yiming Mu, Guoqi Wang
exaly +5 more sources
Renal Failure, 2019 Background: Eldecalcitol (ELD) is an active vitamin D3 analog that is widely used in Japan for the treatment of osteoporosis. The most common adverse drug reaction of ELD is hypercalcemia.
Shunsuke Yamada +2 more
exaly +3 more sources
Eldecalcitol prevents muscle loss by suppressing PI3K/AKT/FOXOs pathway in orchiectomized mice [PDF]
Frontiers in Pharmacology, 2022 Elderly male patients are susceptible to develop osteoporosis and sarcopenia, especially those with fragility fractures, hypogonadism, and prostate cancer with androgen deprivation therapy.
Haichao Zhang +7 more
doaj +2 more sources
Distribution effect of SOST on alveolar bone micro-bone formation in rats induced by Eldecalcitol [PDF]
European Journal of Medical ResearchObjectives This study controlled experimental and histological study based on an ovariectomized (OVX) rat model, and aimed to clarify the distribution changes of TRAP-positive osteoclasts and sclerostin-positive osteocytes in the alveolar septal area of ...
Ying Guo +5 more
doaj +2 more sources
Comparative effectiveness of bone-protective interventions for aromatase inhibitors-induced bone loss in postmenopausal women with early breast cancer: a network meta-analysis [PDF]
Frontiers in OncologyObjectivesThis network meta-analysis (NMA) aims to compare the efficacy of bone-protective interventions in preventing AIs-induced bone loss at lumbar spine and hip sites.MethodsWe systematically searched PubMed, Embase, Cochrane Library, Web of Science,
Yonghui Xu +4 more
doaj +2 more sources
Frontiers in Pharmacology, 2023 Background: Aging and oxidative stress are considered to be the proximal culprits of postmenopausal osteoporosis. Eldecalcitol (ED-71), a new active vitamin D derivative, has shown a good therapeutic effect on different types of osteoporosis, but the ...
Yuying Kou
exaly +3 more sources
Site-Specific Responses to SERM Treatment in Postmenopausal Osteoporosis: No Clear Age Attenuation in a Real-World Study [PDF]
MedicinaBackground: Selective estrogen receptor modulators (SERMs) are widely used for postmenopausal osteoporosis, yet whether treatment response attenuates with aging in routine practice remains unclear.
Takashi Nagai +8 more
doaj +2 more sources
A Case of Milk-Alkali Syndrome Caused by Diuretic-Induced Alkalosis and Polypharmacy [PDF]
Medicina, 2023 Milk-alkali syndrome, which is characterized by hypercalcemia, metabolic alkalosis, and renal dysfunction, typically results from the ingestion of large amounts of calcium and absorbable alkaline products.
Naoya Mizutani +2 more
doaj +2 more sources